Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Apellis Pharmaceuticals Inc
(NQ:
APLS
)
40.11
+0.97 (+2.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 23, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Apellis Pharmaceuticals Inc
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Wedbush Just Raised its Price Target on These 7 Stocks: August 12, 2024
August 13, 2024
New Wedbush price targets have been issued for each of the following seven stocks, including a few that may come as a surprise to some.
Via
InvestorPlace
Apellis Pharmaceuticals' Pegcetacoplan Meets Primary Goal In Late-Stage Study In Patients With Rare Kidney Diseases
August 08, 2024
Swedish Orphan Biovitrum and Apellis Pharmaceuticals released topline results from the Phase 3 VALIANT study of pegcetacoplan for C3 glomerulopathy and IC-MPGN. The study met primary and secondary...
Via
Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
August 02, 2024
Via
Benzinga
Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights
July 17, 2024
Via
Benzinga
What Analysts Are Saying About Apellis Pharmaceuticals Stock
June 28, 2024
Via
Benzinga
Nike, Accolade And Other Big Stocks Moving Lower In Friday's Pre-Market Session
June 28, 2024
Via
Benzinga
Expert Outlook: Apellis Pharmaceuticals Through The Eyes Of 15 Analysts
May 28, 2024
Via
Benzinga
In-Depth Examination Of 14 Analyst Recommendations For Apellis Pharmaceuticals
May 08, 2024
Via
Benzinga
APLS Stock Earnings: Apellis Pharmaceuticals Misses EPS, Beats Revenue for Q1 2024
May 07, 2024
APLS stock results show that Apellis Pharmaceuticals missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Expert Ratings For Apellis Pharmaceuticals
April 15, 2024
Via
Benzinga
If You Invested $1000 In This Stock 5 Years Ago, You Would Have $3,000 Today
April 10, 2024
Via
Benzinga
$1000 Invested In This Stock 5 Years Ago Would Be Worth $3,000 Today
March 29, 2024
Via
Benzinga
Decoding 15 Analyst Evaluations For Apellis Pharmaceuticals
March 27, 2024
Via
Benzinga
Peering Into Apellis Pharmaceuticals's Recent Short Interest
March 15, 2024
Via
Benzinga
Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
February 28, 2024
Via
Benzinga
Earnings Scheduled For February 27, 2024
February 27, 2024
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report quarterly loss at $0.07 per share on revenue of $100.49 million.
Via
Benzinga
Here's How Much You Would Have Made Owning Apellis Pharmaceuticals Stock In The Last 5 Years
February 22, 2024
Via
Benzinga
$1000 Invested In Apellis Pharmaceuticals 5 Years Ago Would Be Worth This Much Today
February 05, 2024
Via
Benzinga
ICU Medical To Rally Around 28%? Here Are 10 Top Analyst Forecasts For Wednesday
February 28, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Pinterest To Rally Over 20%? Here Are 10 Top Analyst Forecasts For Monday
February 05, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Critical Insights From Apellis Pharmaceuticals Analyst Ratings: What You Need To Know
January 30, 2024
Via
Benzinga
Netflix To Rally Around 18%? Here Are 10 Top Analyst Forecasts For Wednesday
January 24, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
Apellis Pharmaceuticals Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)
January 09, 2024
Via
Benzinga
Netflix To Rally Over 13%? Here Are 10 Top Analyst Forecasts For Wednesday
January 17, 2024
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
January 15, 2024
Via
Benzinga
10 Health Care Stocks With Whale Alerts In Today's Session
December 25, 2023
Via
Benzinga
Karuna Therapeutics Jumps Following Takeover By Bristol Myers, Joins Rocket Lab USA, Altair Engineering And Other Big Stocks Moving Higher On Friday
December 22, 2023
U.S. stocks traded higher, with the Dow Jones index gaining around 50 points on Friday. Shares of Karuna Therapeutics, Inc. (NASDAQ: KRTX) rose sharply during Friday’s session following acquisition...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Why Is Complement-Mediated Focused Annexon Stock Trading Higher Today?
December 21, 2023
On Wednesday, Annexon Inc (NASDAQ: ANNX) reported results from the Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) healthy volunteer study of ANX1502 that targets the active form...
Via
Benzinga
Micron Technology To Rally Over 15%? Here Are 10 Top Analyst Forecasts For Friday
December 15, 2023
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Via
Benzinga
US Stocks Eye 7-Day Winning Streak As Mortgage Rates Fall Below 7%, Yields Tumble: What's Driving Markets Thursday?
December 14, 2023
It’s shaping up to be a positive Thursday on Wall Street, with risk sentiment remaining robust after the Federal Reserve effectively opened the door to rate cuts in 2024.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
10
11
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.